AMD Stock Recent News
AMD LATEST HEADLINES
The leaders of America's chip giants cheered the president's artificial intelligence orders, which could help boost the domestic semiconductor industry.
The semiconductor industry is at the heart of the artificial intelligence (AI) revolution. Without the thousands of graphics processing units (GPUs) that fill each specialized data center, developing the most advanced AI software applications wouldn't be possible.
AMD CEO Lisa Su says that the chipmaker will start sourcing in Arizona this year, but it'll still be hard work and a multi-year process https://bloom.bg/44J2Y3E Corrects manufacturing to sourcing
Physical AI, which bridges today's digitally focused AI to machines, robots, and devices that can interact in real-time, learning and adapting along the way, is the future of AI.
In the most recent trading session, Advanced Micro Devices (AMD) closed at $154.72, indicating a -1.45% shift from the previous trading day.
Advanced Micro Devices (AMD -1.31%) stock has headed lower in Tuesday's trading, but it's also regained some ground from sell-offs at the beginning of the session. The semiconductor company's share price was down 1.5% as of 3 p.m.
Bernstein has raised its price target on Advanced Micro Devices (NASDAQ: AMD) to $140 from $95, citing the company's growing role in the artificial intelligence hardware race.
Cathie Wood is on a roll this year. The CEO, co-founder, and primary investor at Ark Invest isn't going to play it safe to lock in her market-thumping gains in 2025.
Discover the "Catalyst Monitor Q3 2025" report, offering insights from KOLs on 18 significant catalysts, including FDA approvals for Ascendis Pharma, PTC Therapeutics, Lenz Therapeutics, and more. It provides crucial intel on trial timelines and market trends, crucial for biopharma milestones in Q3 2025. Discover the "Catalyst Monitor Q3 2025" report, offering insights from KOLs on 18 significant catalysts, including FDA approvals for Ascendis Pharma, PTC Therapeutics, Lenz Therapeutics, and more. It provides crucial intel on trial timelines and market trends, crucial for biopharma milestones in Q3 2025.